- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03992339
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SEARCH)
March 27, 2023 updated by: Antengene Corporation
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This is an open-label, single arm, and registered study of ATG-010 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
This is an open-label, single arm, and registered study.
About 60 patients with relapsed/refractory DLBCL plan to be enrolled in about 10 study sites of the study.
It is planned that at least 50% (~30 patients) will have the GCB subtype of DLBCL.
Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.
Patients should remain on the study treatment of ATG-010, until either PD or occurrence of unacceptable toxicity.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jasmine Sun, MD
- Phone Number: 13701803117
- Email: jasmine.sun@antengene.com
Study Contact Backup
- Name: Stacey Chen, MD
- Email: stacey.chen@antengene.com
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230000
- Anhui Province Cancer Hospital
-
-
Beijing
-
Beijing, Beijing, China, 100191
- Peking University Third Hospital
-
Beijing, Beijing, China, 100142
- Beijing Cancer Hospital
-
-
Chongqing
-
Chongqing, Chongqing, China, 400000
- Chongqing Universtity Cancer Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Sun Yat-sen University Cancer Center
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Wuhan Union Hospital
-
Wuhan, Hubei, China, 430000
- Hubei Cancer Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- The First Affilate Hospital with Nanjing Medical University
-
-
Jilin
-
Chang chun, Jilin, China, 130021
- The First Bethune Hospital of Jilin University
-
-
Liaoning
-
Dalian, Liaoning, China, 116027
- The Second Hospital of Dalian Medical University
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Fudan University Shanghai Cancer Center
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital of Sichuan University
-
-
Tianjin
-
Tianjin, Tianjin, China, 300060
- TianJin Medical University Cancer Institute & Hospital
-
Tianjin, Tianjin, China, 300052
- Tianjin blood research institute
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Cancer Hospital of the University of the Chinese Academy of Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patient must provide informed consent form (ICF) prior to the first screening procedure.
- Age ≥18 years.
- ECOG performance status of ≤ 2.
- Patients should have estimated life expectancy of >3 months at study entry.
- Previously treated, pathologically confirmed de novo DLBCL, or DLBCL transformed from previously diagnosed indolent lymphoma (e.g., follicular lymphoma).
- Patients must have received at least 2 but no more than 5 previous systemic regimens for the treatment of their de novo or transformed DLBCL.
- Documented clinical or radiographic evidence of progressive DLBCL prior to dosing.
- Patients must have measurable disease per the revised criteria for response assessment of lymphoma (Cheson, 2014).
- Patients must not be eligible for high-dose chemotherapy with autologous stem cell transplantation rescue.
Exclusion Criteria:
- Patients who are pregnant or lactating.
- DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma, composite lymphoma (Hodgkin's lymphoma +NHL), or DLBCL transformed from diseases other than indolent NHL or Richter's.
- Primary mediastinal (thymic) large B-cell lymphoma.
- Known central nervous system lymphoma or meningeal involvement.
- Patients whose most recent systemic anticancer therapy include radiation, chemotherapy, immunotherapy, radio-immunotherapy, or any other anticancer therapy other than glucocorticoids < 6 weeks prior to first dose of study drug.
- Patients who have not recovered to Grade ≤ 1 clinically significant adverse events, or to their baseline, from their most recent systemic anti-DLBCL therapy.
- Patients with active graft-versus-host disease after allogeneic stem cell transplantation. At least 4 months must have elapsed since completion of allogeneic stem cell transplantation.
- Major surgery within 2 weeks of first dose of study treatment of ATG-010.
- Any life-threatening illness, medical condition or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety.
- Active hepatitis B virus or hepatitis C virus infection.
- Known human immunodeficiency virus infection.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ATG-010
Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010.
|
Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: 6 months after the last subject was enrolled
|
Percentage of subjects with PR, or CR
|
6 months after the last subject was enrolled
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DOR
Time Frame: 6 months after the last subject was enrolled
|
Duration of time from first occurrence of CR or PR until the first date that disease progression is objectively documented
|
6 months after the last subject was enrolled
|
DCR
Time Frame: 6 months after the last subject was enrolled
|
Proportion of patients who achieve CR, PR, or SD for a minimum of 4 weeks, following the first dose of study drug (i.e., CR+PR+SD)
|
6 months after the last subject was enrolled
|
OS
Time Frame: 6 months after the last subject was enrolled
|
Duration of time from the first dose of study drug until death due to any cause
|
6 months after the last subject was enrolled
|
PFS
Time Frame: 6 months after the last subject was enrolled
|
Duration of time from the first dose of study drug until progression or death due to any cause
|
6 months after the last subject was enrolled
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Bingshan Liu, MD, Medical Monitor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 9, 2020
Primary Completion (Anticipated)
December 1, 2023
Study Completion (Anticipated)
June 30, 2024
Study Registration Dates
First Submitted
June 18, 2019
First Submitted That Met QC Criteria
June 18, 2019
First Posted (Actual)
June 20, 2019
Study Record Updates
Last Update Posted (Actual)
March 29, 2023
Last Update Submitted That Met QC Criteria
March 27, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATG-010-DLBCL-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
-
Curis, Inc.The Leukemia and Lymphoma SocietyCompletedLymphoma | Refractory Lymphoma | Relapsed Lymphoma | Relapsed and/or Refractory Lymphoma | Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Double-hit Lymphoma (DHL) | Triple-hit Lymphoma... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
AmgenMerck Sharp & Dohme LLCCompletedRelapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)United States, Germany, Spain, Australia, Netherlands, France
-
Technische Universität DresdenGerman Cancer Research CenterRecruitingNeoplasms | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)Germany
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Kite, A Gilead CompanyActive, not recruitingRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)United States, Spain, United Kingdom, Canada, Netherlands, Germany, France, Sweden, Israel, Switzerland, Belgium, Australia, Austria, Italy
-
Kite, A Gilead CompanyApproved for marketingRelapsed/Refractory Diffuse Large B Cell Lymphoma | Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | Relapsed/Refractory Transformed Follicular Lymphoma | Relapsed/Refractory High-Grade B-Cell LymphomaUnited States
-
ADC Therapeutics S.A.No longer availableRelapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
-
Regeneron PharmaceuticalsAvailableDiffuse Large B-Cell Lymphoma (DLBCL) | Relapsed or Refractory (R/R) Follicular Lymphoma (FL) | B-Cell Non-Hodgkin Lymphoma (NHL) | High-Grade B-Cell Lymphoma (HGBCL)
-
Curocell Inc.RecruitingHigh-grade B-cell Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Transformed Follicular Lymphoma (TFL) | Refractory Large B-cell Lymphoma | Relapsed Large B-cell LymphomaKorea, Republic of
Clinical Trials on ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
-
Shanghai Antengene Corporation LimitedTerminatedAdvanced Solid TumorsChina
-
Federal Budgetary Research Institution State Research...CompletedSmallpox | Monkeypox | Cowpox | Vaccinia Virus InfectionRussian Federation
-
Memorial Sloan Kettering Cancer CenterTufts Medical Center; Lahey ClinicCompleted
-
Memorial Sloan Kettering Cancer CenterBoehringer Ingelheim; National Comprehensive Cancer NetworkCompletedHead and Neck Cancer | Squamous Cell CancerUnited States